Despite the significant increase of our knowledge about carcinogenesis and recent successful development of innovative cancer drugs, including targeted therapies and immunotherapies, cancer mortality has only slightly decreased in the past decades. Cancer early detection is probably the most cost-effective means to reduce cancer mortality as prognosis is much better when cancer is detected and treated at the early stage.

SeekIn is a startup focusing on blood-based cancer early diagnosis with a mission to reduce cancer mortality by 10% in the screened population by 2030. Our proprietary ctDNA mutation detection technology has demonstrated its promise to identify asymptomatic cancer patients from general population.

SeekIn was featured by Biocentury Innovations